BeOne Medicines (BEIGF) Free Cash Flow Growth (1y) (2016 - 2026)
Powered by 
Analysis
BeOne Medicines (BEIGF) Free Cash Flow Growth (1y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.95 Bn | 625.20 Bn | 17.26 Bn | 157.32% |
| 2 | AbbVie | 441.39 Bn | 434.82 Bn | 12.70 Bn | -36.24% |
| 3 | Merck | 366.72 Bn | 359.58 Bn | 12.21 Bn | 77.03% |
| 4 | Novartis Ag | 266.68 Bn | 258.99 Bn | 11.24 Bn | -11.32% |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | 125.17% |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | 107.90% |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 8 | Incyte | 25.50 Bn | 20.96 Bn | 1.57 Bn | 1,829.52% |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn | 58.76% |
| 10 | BeOne Medicines | 2.48 Bn | -2.62 Bn | 1.53 Bn | 96.00% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 96.00% |
| Mar 31, 2026 | 1,092.51% |
| Dec 31, 2025 | 2,292.98% |
| Sep 30, 2025 | 547.86% |
| Jun 30, 2025 | 208.68% |
| Mar 31, 2025 | 96.58% |
| Dec 31, 2024 | 95.43% |
| Sep 30, 2024 | 123.18% |
| Jun 30, 2024 | 50.52% |
| Mar 31, 2024 | 32.52% |
| Dec 31, 2023 | 13.87% |
| Sep 30, 2023 | 64.80% |
| Jun 30, 2023 | -0.66% |
| Mar 31, 2023 | -130.33% |
| Dec 31, 2022 | 29.43% |
| Sep 30, 2022 | -19.16% |
| Jun 30, 2022 | 10.06% |
| Mar 31, 2022 | -461.88% |
| Dec 31, 2021 | -69.69% |
| Sep 30, 2021 | -50.10% |